Senesco Technologies, Inc.  

(Public, OTCBB:SNTI)   Watch this stock  
Find more results for Steve Rector�
+0.02 (1.16%)
Aug 29 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.74 - 1.79
52 week 1.58 - 6.35
Open 1.79
Vol / Avg. 10,011.00/29,206.00
Mkt cap 12.02M
P/E     -
Div/yield     -
EPS -3.25
Shares 6.91M
Beta 1.08
Inst. own 0%
Jun 25, 2014
Senesco Technologies Inc. Conference Presentation

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.06% -87.14%
Return on average equity -229.99% -193.00%
Employees 20 -
CDP Score - -


Suite 130, 721 Route 202/206
United States - Map
+1-908-8644444 (Phone)
+1-908-8644440 (Fax)

Website links


Senesco Technologies, Inc. is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants. In March 2014, the Company opened two new sites in Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. In May 2014, the Company acquired Fabrus, Inc.

Officers and directors

Harlan W. Waksal M.D. Chairman of the Board
Age: 60
Leslie J. Browne Ph.D. President
Age: 64
Ronald A. Martell Chief Executive Officer, Director
Age: 50
Joel P. Brooks Chief Financial Officer, Treasurer, Secretary
Age: 55
Trading Activity - Yahoo Finance
John E. Thompson Ph.D. Executive Vice President
Age: 72
James Graziano Ph.D. Chief Technology Officer
Vaughn Smider M.D., Ph.D. Chief Scientific Officer, Director
Miguel de los Rios Ph.D. Vice President - Research
David S. Rector Lead Independent Director
Age: 67
Phillip Frost M.D. Director